2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network

Kazuomi Kario; Sungha Park; Yook Chin Chia; Apichard Sukonthasarn; Yuda Turana; Jinho Shin; Chen Huan Chen; Peera Buranakitjaroen; Romeo Divinagracia; Jennifer Nailes; Satoshi Hoshide; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Jam Chin Tay; Boon Wee Teo; Yu Qing Zhang; Huynh Van Minh; Naoko Tomitani; Tomoyuki Kabutoya; Narsingh Verma; Tzung Dau Wang; Ji Guang Wang

doi:10.1111/jch.13751

2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network

Kazuomi Kario, Sungha Park, Yook Chin Chia, Apichard Sukonthasarn, Yuda Turana, Jinho Shin, Chen Huan Chen, Peera Buranakitjaroen, Romeo Divinagracia, Jennifer Nailes, Satoshi Hoshide, Saulat Siddique, Jorge Sison, Arieska Ann Soenarta, Guru Prasad Sogunuru, Jam Chin Tay, Boon Wee Teo, Yu Qing Zhang, Huynh Van Minh, Naoko TomitaniTomoyuki Kabutoya, Narsingh Verma, Tzung Dau Wang, Ji Guang Wang

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

48 Citations (Scopus)

Abstract

Hypertension professionals from Asia have been meeting together for the last decade to discuss how to improve the management of hypertension. Based on these education and research activities, the Hypertension, brain, cardiovascular and renal Outcome Prevention and Evidence in Asia (HOPE Asia) Network was officially established in June 2018 and includes experts from 12 countries/regions across Asia. Among the numerous research and review papers published by members of the HOPE Asia Network since 2017, publications in three key areas provide important guidance on the management of hypertension in Asia. This article highlights key consensus documents, which relate to the Asian characteristics of hypertension, home blood pressure monitoring (HBPM), and ambulatory blood pressure monitoring (ABPM). Hypertension and hypertension-related diseases are common in Asia, and their characteristics differ from those in other populations. It is essential that these are taken into consideration to provide the best opportunity for achieving “perfect 24-hour blood pressure control”, guided by out-of-office (home and ambulatory) blood pressure monitoring. These region-specific consensus documents should contribute to optimizing individual and population-based hypertension management strategies in Asian country. In addition, the HOPE Asia Network model provides a good example of the local interpretation, modification, and dissemination of international best practice to benefit specific populations.

Original language	English
Pages (from-to)	351-362
Number of pages	12
Journal	Journal of Clinical Hypertension
Volume	22
Issue number	3
DOIs	https://doi.org/10.1111/jch.13751
Publication status	Published - 2020 Mar 1

Bibliographical note

Funding Information:
We appreciate two key mentors, Dr Michael A Weber, Dr Daniel T Lackland?and Dr Aletta E Schutte, for their heartfelt advice and support on our HOPE Asia Network activity. We also thank Pfizer, Daichi Sankyo, Omron Healthcare, A&D and Fukuda Denshi Co. Ltd. for the grants to support HOPE Asia Network activities. Medical writing assistance was provided by Nicola Ryan, independent medical writer.

Funding Information:
K Kario received research grants from Omron Healthcare, A&D, and Fukuda Denshi Co. Ltd. S Park has received research grants and honoraria from Pfizer. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. R Divinagracia has received honoraria as a member of speaker's bureaus for Bayer, Novartis, and Pfizer. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. BW TEO has received honoraria for lectures and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim, Servier, MSD, and Novartis. TD Wang has served as an advisor for Medtronic and Omron Healthcare; has served as a speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Novartis, Pfizer, and Sanofi; and has received research grants/support from Abbott, Medtronic, and Novartis. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, HanHui, Merck, Omron, Salubris, Servier and Takeda. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jch.13751

Cite this

Kario, K., Park, S., Chia, Y. C., Sukonthasarn, A., Turana, Y., Shin, J., Chen, C. H., Buranakitjaroen, P., Divinagracia, R., Nailes, J., Hoshide, S., Siddique, S., Sison, J., Soenarta, A. A., Sogunuru, G. P., Tay, J. C., Teo, B. W., Zhang, Y. Q., Van Minh, H., ... Wang, J. G. (2020). 2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network. Journal of Clinical Hypertension, 22(3), 351-362. https://doi.org/10.1111/jch.13751

@article{221e2fbab37c407b917caa6182502f1a,

title = "2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network",

abstract = "Hypertension professionals from Asia have been meeting together for the last decade to discuss how to improve the management of hypertension. Based on these education and research activities, the Hypertension, brain, cardiovascular and renal Outcome Prevention and Evidence in Asia (HOPE Asia) Network was officially established in June 2018 and includes experts from 12 countries/regions across Asia. Among the numerous research and review papers published by members of the HOPE Asia Network since 2017, publications in three key areas provide important guidance on the management of hypertension in Asia. This article highlights key consensus documents, which relate to the Asian characteristics of hypertension, home blood pressure monitoring (HBPM), and ambulatory blood pressure monitoring (ABPM). Hypertension and hypertension-related diseases are common in Asia, and their characteristics differ from those in other populations. It is essential that these are taken into consideration to provide the best opportunity for achieving “perfect 24-hour blood pressure control”, guided by out-of-office (home and ambulatory) blood pressure monitoring. These region-specific consensus documents should contribute to optimizing individual and population-based hypertension management strategies in Asian country. In addition, the HOPE Asia Network model provides a good example of the local interpretation, modification, and dissemination of international best practice to benefit specific populations.",

author = "Kazuomi Kario and Sungha Park and Chia, {Yook Chin} and Apichard Sukonthasarn and Yuda Turana and Jinho Shin and Chen, {Chen Huan} and Peera Buranakitjaroen and Romeo Divinagracia and Jennifer Nailes and Satoshi Hoshide and Saulat Siddique and Jorge Sison and Soenarta, {Arieska Ann} and Sogunuru, {Guru Prasad} and Tay, {Jam Chin} and Teo, {Boon Wee} and Zhang, {Yu Qing} and {Van Minh}, Huynh and Naoko Tomitani and Tomoyuki Kabutoya and Narsingh Verma and Wang, {Tzung Dau} and Wang, {Ji Guang}",

note = "Funding Information: We appreciate two key mentors, Dr Michael A Weber, Dr Daniel T Lackland?and Dr Aletta E Schutte, for their heartfelt advice and support on our HOPE Asia Network activity. We also thank Pfizer, Daichi Sankyo, Omron Healthcare, A&D and Fukuda Denshi Co. Ltd. for the grants to support HOPE Asia Network activities. Medical writing assistance was provided by Nicola Ryan, independent medical writer. Funding Information: K Kario received research grants from Omron Healthcare, A&D, and Fukuda Denshi Co. Ltd. S Park has received research grants and honoraria from Pfizer. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. R Divinagracia has received honoraria as a member of speaker's bureaus for Bayer, Novartis, and Pfizer. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. BW TEO has received honoraria for lectures and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim, Servier, MSD, and Novartis. TD Wang has served as an advisor for Medtronic and Omron Healthcare; has served as a speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Novartis, Pfizer, and Sanofi; and has received research grants/support from Abbott, Medtronic, and Novartis. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, HanHui, Merck, Omron, Salubris, Servier and Takeda. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2020",

month = mar,

day = "1",

doi = "10.1111/jch.13751",

language = "English",

volume = "22",

pages = "351--362",

journal = "Journal of Clinical Hypertension",

issn = "1524-6175",

publisher = "Wiley-Blackwell",

number = "3",

}

Kario, K, Park, S, Chia, YC, Sukonthasarn, A, Turana, Y, Shin, J, Chen, CH, Buranakitjaroen, P, Divinagracia, R, Nailes, J, Hoshide, S, Siddique, S, Sison, J, Soenarta, AA, Sogunuru, GP, Tay, JC, Teo, BW, Zhang, YQ, Van Minh, H, Tomitani, N, Kabutoya, T, Verma, N, Wang, TD & Wang, JG 2020, '2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network', Journal of Clinical Hypertension, vol. 22, no. 3, pp. 351-362. https://doi.org/10.1111/jch.13751

TY - JOUR

T1 - 2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network

AU - Kario, Kazuomi

AU - Park, Sungha

AU - Chia, Yook Chin

AU - Sukonthasarn, Apichard

AU - Turana, Yuda

AU - Shin, Jinho

AU - Chen, Chen Huan

AU - Buranakitjaroen, Peera

AU - Divinagracia, Romeo

AU - Nailes, Jennifer

AU - Hoshide, Satoshi

AU - Siddique, Saulat

AU - Sison, Jorge

AU - Soenarta, Arieska Ann

AU - Sogunuru, Guru Prasad

AU - Tay, Jam Chin

AU - Teo, Boon Wee

AU - Zhang, Yu Qing

AU - Van Minh, Huynh

AU - Tomitani, Naoko

AU - Kabutoya, Tomoyuki

AU - Verma, Narsingh

AU - Wang, Tzung Dau

AU - Wang, Ji Guang

N1 - Funding Information: We appreciate two key mentors, Dr Michael A Weber, Dr Daniel T Lackland?and Dr Aletta E Schutte, for their heartfelt advice and support on our HOPE Asia Network activity. We also thank Pfizer, Daichi Sankyo, Omron Healthcare, A&D and Fukuda Denshi Co. Ltd. for the grants to support HOPE Asia Network activities. Medical writing assistance was provided by Nicola Ryan, independent medical writer. Funding Information: K Kario received research grants from Omron Healthcare, A&D, and Fukuda Denshi Co. Ltd. S Park has received research grants and honoraria from Pfizer. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. R Divinagracia has received honoraria as a member of speaker's bureaus for Bayer, Novartis, and Pfizer. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. BW TEO has received honoraria for lectures and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim, Servier, MSD, and Novartis. TD Wang has served as an advisor for Medtronic and Omron Healthcare; has served as a speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Novartis, Pfizer, and Sanofi; and has received research grants/support from Abbott, Medtronic, and Novartis. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, HanHui, Merck, Omron, Salubris, Servier and Takeda. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article. Publisher Copyright: © 2019 Wiley Periodicals, Inc.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Hypertension professionals from Asia have been meeting together for the last decade to discuss how to improve the management of hypertension. Based on these education and research activities, the Hypertension, brain, cardiovascular and renal Outcome Prevention and Evidence in Asia (HOPE Asia) Network was officially established in June 2018 and includes experts from 12 countries/regions across Asia. Among the numerous research and review papers published by members of the HOPE Asia Network since 2017, publications in three key areas provide important guidance on the management of hypertension in Asia. This article highlights key consensus documents, which relate to the Asian characteristics of hypertension, home blood pressure monitoring (HBPM), and ambulatory blood pressure monitoring (ABPM). Hypertension and hypertension-related diseases are common in Asia, and their characteristics differ from those in other populations. It is essential that these are taken into consideration to provide the best opportunity for achieving “perfect 24-hour blood pressure control”, guided by out-of-office (home and ambulatory) blood pressure monitoring. These region-specific consensus documents should contribute to optimizing individual and population-based hypertension management strategies in Asian country. In addition, the HOPE Asia Network model provides a good example of the local interpretation, modification, and dissemination of international best practice to benefit specific populations.

AB - Hypertension professionals from Asia have been meeting together for the last decade to discuss how to improve the management of hypertension. Based on these education and research activities, the Hypertension, brain, cardiovascular and renal Outcome Prevention and Evidence in Asia (HOPE Asia) Network was officially established in June 2018 and includes experts from 12 countries/regions across Asia. Among the numerous research and review papers published by members of the HOPE Asia Network since 2017, publications in three key areas provide important guidance on the management of hypertension in Asia. This article highlights key consensus documents, which relate to the Asian characteristics of hypertension, home blood pressure monitoring (HBPM), and ambulatory blood pressure monitoring (ABPM). Hypertension and hypertension-related diseases are common in Asia, and their characteristics differ from those in other populations. It is essential that these are taken into consideration to provide the best opportunity for achieving “perfect 24-hour blood pressure control”, guided by out-of-office (home and ambulatory) blood pressure monitoring. These region-specific consensus documents should contribute to optimizing individual and population-based hypertension management strategies in Asian country. In addition, the HOPE Asia Network model provides a good example of the local interpretation, modification, and dissemination of international best practice to benefit specific populations.

UR - http://www.scopus.com/inward/record.url?scp=85076206246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076206246&partnerID=8YFLogxK

U2 - 10.1111/jch.13751

DO - 10.1111/jch.13751

M3 - Review article

C2 - 31816164

AN - SCOPUS:85076206246

SN - 1524-6175

VL - 22

SP - 351

EP - 362

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

IS - 3

ER -

2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this